The therapeuatic effect of Endostar on soft carotid plaque neovascularization in patients with non-small cell lung cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      Angiogenesis Inhibitors/*administration & dosage ; Carcinoma, Non-Small-Cell Lung/*drug therapy ; Endostatins/*administration & dosage ; Neovascularization, Pathologic/*drug therapy ; Plaque, Atherosclerotic/*drug therapy; Aged ; Carcinoma, Non-Small-Cell Lung/complications ; Carcinoma, Non-Small-Cell Lung/pathology ; Carotid Arteries/drug effects ; Carotid Arteries/pathology ; Cisplatin/administration & dosage ; Contrast Media ; Endostatins/genetics ; Female ; Humans ; Male ; Middle Aged ; Neovascularization, Pathologic/complications ; Neovascularization, Pathologic/pathology ; Plaque, Atherosclerotic/complications ; Plaque, Atherosclerotic/pathology ; Recombinant Proteins ; Vinblastine/administration & dosage ; Vinblastine/analogs & derivatives ; Vinorelbine
    • Abstract:
      The purpose of this study was to investigate the effect of the angiogenesis inhibitor Endostar on carotid plaque neovascularization in patients with non-small cell lung cancer (NSCLC) using contrast-enhanced ultrasound (CEUS). Ninety-one patients who had NSCLC with soft carotid plaques were selected for treatment either with the NP regimen (vinorelbine + cisplatin) (43 patients) or with the ENP regimen (Endostar + NP) (48 patients). Plaque thickness and neovascularization of the plaque were assessed before and at 1 month after treatment using CEUS. Enhanced intensity (EI) of CEUS was used for quantification of plaque neovascularization. There was no significant changes in any group in thickness of plaque between recruitment and 1 month after treatment (P > 0.05 for all). There was no significant change in the EI of plaque in the controls or NP groups at 1 month after treatment (P > 0.05), while EI in the ENP group was significantly reduced at 1 month after treatment (P < 0.01) and significantly lower than that in the controls or NP group at 1 month after treatment (P < 0.001 both). This study indicates that carotid soft plaque neovascularization in patients with NSCLC can be reduced by anti-angiogenesis treatment.
    • References:
      J Thorac Oncol. 2011 Jun;6(6):1104-9. (PMID: 21532504)
      Ultrasound Med Biol. 2014 Jun;40(6):1318-28. (PMID: 24613639)
      Curr Atheroscler Rep. 2001 May;3(3):225-33. (PMID: 11286644)
      Am J Cardiol. 2004 Jun 3;93(11A):32C-48C. (PMID: 15178515)
      Vasc Med. 2004 Feb;9(1):7-12. (PMID: 15230482)
      Circulation. 2004 Oct 5;110(14):2032-8. (PMID: 15451780)
      Circulation. 1999 Apr 6;99(13):1726-32. (PMID: 10190883)
      Circulation. 2004 Nov 2;110(18):2843-50. (PMID: 15505090)
      Eur Radiol. 2004 Oct;14 Suppl 8:P4-10. (PMID: 15700327)
      J Am Coll Cardiol. 2006 Jul 18;48(2):236-43. (PMID: 16843169)
      J Am Coll Cardiol. 2007 May 29;49(21):2073-80. (PMID: 17531655)
      Biochem Biophys Res Commun. 2007 Sep 14;361(1):79-84. (PMID: 17644065)
      Vasc Med. 2007 Nov;12(4):291-7. (PMID: 18048465)
      Ann Oncol. 2008 May;19(5):927-34. (PMID: 18056916)
      J Am Coll Cardiol. 2008 Dec 2;52(23):1847-57. (PMID: 19038682)
      Eur J Pharmacol. 2009 Jul 1;614(1-3):1-6. (PMID: 19389394)
      Cancer Sci. 2009 Aug;100(8):1510-9. (PMID: 19459845)
      Circ Cardiovasc Imaging. 2009 Sep;2(5):391-6. (PMID: 19808627)
      Oncologist. 2010;15(2):130-41. (PMID: 20139170)
      J Zhejiang Univ Sci B. 2010 Aug;11(8):599-607. (PMID: 20669350)
      Radiology. 2011 Feb;258(2):618-26. (PMID: 20971776)
      Atherosclerosis. 2011 Feb;214(2):295-300. (PMID: 21130458)
      J Hypertens. 2012 Jan;30(1):107-16. (PMID: 22134386)
      AJR Am J Roentgenol. 2012 Jan;198(1):W13-9. (PMID: 22194509)
      Invest New Drugs. 2012 Jun;30(3):1144-9. (PMID: 21225314)
      Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1272-7. (PMID: 22099051)
      World J Surg Oncol. 2012;10:170. (PMID: 22917490)
      Ultrasound Med Biol. 2014 Jan;40(1):25-36. (PMID: 24161799)
      PLoS One. 2014;9(4):e92445. (PMID: 24713618)
      Cancer Chemother Pharmacol. 2011 Oct;68(4):1027-32. (PMID: 21327933)
    • Accession Number:
      0 (Angiogenesis Inhibitors)
      0 (Contrast Media)
      0 (Endostatins)
      0 (Recombinant Proteins)
      5V9KLZ54CY (Vinblastine)
      GVG18ZDN65 (endostar protein)
      Q20Q21Q62J (Cisplatin)
      Q6C979R91Y (Vinorelbine)
    • Publication Date:
      Date Created: 20150311 Date Completed: 20151209 Latest Revision: 20181202
    • Publication Date:
      20221213
    • Accession Number:
      PMC4354169
    • Accession Number:
      10.1038/srep08956
    • Accession Number:
      25753083